IDEXX LABORATORIES INC /DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
IDEXX LABORATORIES INC /DE (IDXX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $354.19 per share as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-02-20
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $354.19.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $291.25.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $250.14.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $219.90.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2025-12-31 | $354.19 10-K · filed 2026-02-20 | |
| 2024-12-31 | $291.25 10-K · filed 2026-02-20 | |
| 2023-12-31 | $250.14 10-K · filed 2025-02-21 | |
| 2022-12-31 | $219.90 10-K · filed 2024-02-22 | |
| 2021-12-31 | $188.47 10-K · filed 2023-02-16 | |
| 2020-12-31 | $149.32 10-K · filed 2022-02-16 | |
| 2019-12-31 | $117.13 10-K · filed 2021-02-12 | |
| 2018-12-31 | $91.64 10-K · filed 2020-02-14 | |
| 2017-12-31 | $72.72 10-K · filed 2019-02-15 | |
| 2016-12-31 | $57.31 10-K · filed 2018-02-16 | |
| 2015-12-31 | $49.76 10-K · filed 2017-02-17 | |
| 2014-12-31 | $40.08 10-K · filed 2016-02-17 | $80.16 10-K · filed 2015-02-17 |
| 2013-12-31 | $63.96 10-K · filed 2015-02-17 | |
| 2012-12-31 | $52.50 10-K · filed 2014-02-18 | |
| 2011-12-31 | $43.31 10-K · filed 2013-02-19 | |
| 2010-12-31 | $33.34 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |